Autopsy report · NCT04873895

TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)

“failure to accrue”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 2 years 3 months before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Abramson Cancer Center at Penn Medicine

Sponsor type

University, hospital or other

Conditions

Colorectal Neoplasms Malignant

Interventions

Axitinib 5 MG; Hydroxychloroquine Pill; trans arterial chemoembolization

Participants

5

Sites

1

Countries

United States

Trials that died the same way

• A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
  “unable to accrue” (91% match in meaning)
• Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma
  “Insufficient accrual” (89% match in meaning)
• Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
  “Severe lack of accrual” (80% match in meaning)
• Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and "Healthy Controls"
  “Accrual difficulties” (79% match in meaning)
• Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth
  “Inadequate accrual” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.